Citations

Mayo Clinic

Showing 10 of 108522 citations.

B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
Bennett, Jeffrey L. , Pittock, Sean J. , Paul, Friedemann , Kim, Ho Jin , Irani, Sarosh R. , O'Connor, Kevin C., Patterson, Kristina R. , Gunsior, Michele , Mittereder, Nanette , Rees, William A. , Cimbora, Daniel , Pittock, S J , Cree, Bruce Ac , Bennett, Jeffrey L , Irani, Sarosh R , Paul, Friedemann , Smith, Michael A. , Cree, Bruce

Annals of Clinical and Translational Neurology | September 2, 2024 | Volume: 11 | Issue: 10 | Pages: 2792-2798

10.1002/acn3.52171 | PMID 39222408 Get It

Abstract This post hoc analysis of the randomized, placebo‐controlled N‐MOmentum study (NCT02200770) of inebilizumab in neuromyelitis optica spectrum disorder (NMOSD) evaluated relationships between circulating B‐cell subsets and aquaporin‐4 immunoglobulin G (AQP4‐lgG) titers and attacks. Among participants receiving placebo, CD20 + and CD27 + B‐cell counts were modestly increased from the pre‐attack visit to attack; plasmablast/plasma cell gene signature was increased from baseline to the pre‐attack visit ( p = 0.016) and from baseline to attack ( p = 0.009). With inebilizumab treatment, B‐cell subset counts decreased and did not increase with attacks. No difference in change of AQP4‐IgG titers from baseline to time of attack was observed.
Large focal pericardial effusion secondary to coronary artery perforation post complex coronary intervention mimics a mass
Kanaan, Christopher , Cannan, Charles R., Kanaan, Christopher N , Cannan, Charles, Arsanjani, Reza

European Heart Journal - Case Reports | September 2, 2024 | Volume: 8 | Issue: 9 | Pages: No page available

10.1093/ehjcr/ytae470 | PMID 39286726 Get It

493. EFFECTIVENESS OF TRANSORAL INCISIONLESS FUNDOPLICATION (TIF) WITHOUT OR WITH HIATAL HERNIA REPAIR (CTIF) IN PATIENTS WITH GERD AND CHRONIC COUGH
Almario, Jose Antonio , Dunbar, Kerry B., Parker, Brett , Brewer-Gutierrez, Olaya, Janu, Peter , Sohagia, Amit, Khara, Harshit S. , Dayyeh, Barham Abu, Sharaiha, Reem Z. , Zarnegar, Rasa , Ihde, Glenn , Nguyen, Ninh T. , Chang, Kenneth , Swei, Eric C. , Yadlapati, Rena , Murray, Michael J. , Diehl, David L. , Kolb, Jennifer M. , Canto, Marcia Irene

Diseases of the Esophagus | September 2, 2024 | Volume: 37 | Issue: Supplement_1 | Pages: No page available

10.1093/dote/doae057.230 Get It

Abstract Background GERD is a common cause of chronic cough. Although barrier therapy with laparoscopic fundoplication is highly effective for typical GERD symptoms, the response rates are variable for chronic cough. We hypothesized that transoral incisionless fundoplication (TIF) or TIF with hiatal hernia repair (cTIF) may be a suitable alternative for medically refractory cough associated with GERD. Aim We prospectively s studied the effectiveness and safety of TIF/cTIF in patients with chronic cough and proven GERD. Methods Patients with GERD and extra-esophageal symptoms from 10 academic and community medical centers (TIF Registry), elevated GERD-HRQL score +/- Reflux Symptom Index (RSI) >13 and pathologic reflux by esophageal pH-metry, or erosive esophagitis/Barrett’s esophagus were evaluated before and after a minimum 6 months post TIF/cTIF performed by gastroenterologists and surgeons. Patients with history of prior foregut/bariatric surgery, chronic obstructive or interstitial lung disease, or prior lung transplant were excluded. The primary outcome was improvement in RSI score at last follow-up compared to baseline. Secondary outcomes were: 1) normalization of RSI (<13), 2) improvement in cough sub-scores of RSI (decrease ≥ 2 points or to 0 on a 5-point scale), 3) GERD symptom improvement (>50% decrease in GERD-HRQL, or < 2 in all sub-scores) 4) discontinuation of proton pump inhibitor (PPI), and 5) overall patient satisfaction. We further analyzed response in patients with cough-predominant phenotype (chief complaint of cough and RSI troublesome cough subscore ≥2). Results 198 patients with cough and GERD successfully underwent TIF/cTIF (Table 1) without serious adverse events. Greater than 6-month follow-up was available for 177 patients at a median of 12 months [IQR 6,12]. Median RSI score decreased from 18 [IQR 13, 27] to 5 [IQR 2, 11] (p < 0.0001), median change 11 [IQR5,11]. 83% of patients with elevated baseline RSI normalized their scores. 75% of patients had improvement of cough when lying down (median: 1 point [IQR 0,3]), and 72% of patients had improvement of troublesome cough (median: 1 point [IQR 1,3]). 83% of patients successfully discontinued or decreased PPI to occasional use. Patient satisfaction improved from a baseline of 5.6% to 68.8% (p <0.0001). Compared to patients without cough-predominant symptoms, cough-predominant patients (n=108) experienced an additional 4.2-point decrease in in RSI score (p = 0.01) and 1.5-point decrease in troublesome cough sub-scores (p<0.0001). Patients with regurgitation phenotype were more likely to have a favorable cough response at 6 months (p<0.0001). In appropriately selected patients, cTIF and TIF were comparable for cough, GERD-HRQL, RSI, and PPI responses. Conclusion TIF/cTIF are effective and safe alternative barrier therapies for patients with pH-positive cough-predominant GERD.
Blocking IL‐23 Signaling Mitigates Cigarette Smoke‐Induced Murine Emphysema
Tian, Xue, Zhang, Chujie , Vassallo, Robert , Vassallo, Robert , Tian, Xue, Wang, Shaohua , Prakash, Y. S.

Environmental Toxicology | September 2, 2024 | Volume: 39 | Issue: 12 | Pages: 5334-5346

10.1002/tox.24405 | PMID 39221838 Get It

ABSTRACTInflammatory cell infiltration is a characteristic feature of COPD and correlates directly with the severity of the disease. Interleukin‐23 (IL‐23) is a pro‐inflammatory cytokine that regulates Th‐17 inflammation, which mediates many pathophysiological events in COPD. The primary goal of this study was to determine the role of IL‐23 as a mediator of key pathologic processes in cigarette smoke‐induced COPD. In this study, we report an increase in IL23 gene expression in the lung biopsies of COPD patients compared to controls and identified a positive correlation between IL23 gene expression and disease severity. In a cigarette smoke‐induced murine emphysema model, the suppression of IL‐23 with a monoclonal blocking antibody reduced the severity of cigarette smoke‐induced murine emphysema. Mechanistically, the suppression of IL‐23 was associated with a reduction in immune cell infiltration, oxidative stress injury, and apoptosis, suggesting a role for IL‐23 as an essential immune mediator of the inflammatory processes in the pathogenesis of CS‐induced emphysema.
Serial Changes in Ventricular Strain in Symptomatic Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Insights From the VALOR-HCM Trial
Desai, Milind Y. , Okushi, Yuichiro , Gaballa, Andrew , Wang, Qiuqing, Geske, Jeffrey B. , Owens, Anjali , Saberi, Sara , Wang, Andrew , Cremer, Paul , Lakdawala, Neal K. , Tower‐Rader, Albree, Naidu, Srihari S. , Lampl, Kathy, Sehnert, Amy J. , Nissen, Steven E. , Masri, Ahmad , Zenker, M., Wheeler, M., Bach, R., Rader, F., Bajona, Pietro, Owens, Anjali T , Cremer, Paul C , Sherrid, Mark , Lakdawala, Neal K , Tower-Rader, Albree , Naidu, Srihari S , Sehnert, Amy J , Nissen, Steven E , Popovic, Zoran B , Geske, Jeffrey B , Saberi, Sara , Wang, Andrew , Sherrid, Mark V. , Fermin, David , Stendahl, John C. , Orford, J.

Circulation: Cardiovascular Imaging | September 2, 2024 | Volume: 17 | Issue: 9 | Pages: No page available

10.1161/circimaging.124.017185 | PMID 39221824 Get It

BACKGROUND: In severely symptomatic patients with obstructive hypertrophic cardiomyopathy, VALOR-HCM (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy) demonstrated that mavacamten reduces the need for septal reduction therapy with sustained improvement in left ventricular (LV) outflow tract gradients and symptoms. Global longitudinal strain (GLS), a measure of regional myocardial function, is a more sensitive marker of systolic function. In VALOR-HCM, we assessed serial changes in LV and right ventricular (RV) strain. METHODS: VALOR-HCM included 112 patients with symptomatic obstructive hypertrophic cardiomyopathy (mean, 60 years; 51% male; LV ejection fraction, 68%). Patients assigned to mavacamten at baseline continued the drug for 56 weeks (n=56) and those assigned to placebo (n=52) transitioned to mavacamten from weeks 16 to 56 (40-week exposure). LV-GLS and RV-GLS assessment was performed using a vendor-neutral software. Non-foreshortened apical (4-, 3-, and 2-chamber) views were used to obtain peak LV-GLS. RV focused 4-chamber view was used to calculate RV 4-chamber and free wall strain. A more negative strain value is favorable. RESULTS: At baseline, the mean LV-GLS, RV 4-chamber, and free wall strain values were −14.7%, −22.2%, and −16.8%, respectively (all worse than reported normal means). In the total study sample, LV-GLS significantly improved from baseline to week 56 ( P =0.02). Twelve patients had transient reduction in LV ejection fraction (<50%) requiring temporary drug interruption (including 3 permanent discontinuations). The LV-GLS in this subgroup was worse at baseline versus total study population (−11.4%), with no significant worsening from baseline through week 56 ( P =0.64). Both free wall and 4-chamber RV-GLS remained unchanged from baseline to week 56 ( P =0.62 and P =0.56, respectively). CONCLUSIONS: In VALOR-HCM, treatment with mavacamten improved LV-GLS from baseline through week 56 (with no significant worsening of LV-GLS in patients with a reduction in LV ejection fraction ≤50%), suggesting a favorable long-term impact on regional LV systolic function. Additionally, there was no detrimental impact on RV systolic function. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04349072.
Pulsed Field Ablation: A Comprehensive Update
Asirvatham, Samuel J. , Nguyen, Duy Tien, Asirvatham, Samuel J , Ezzeddine, Fatima M.

Journal of Clinical Medicine | September 2, 2024 | Volume: 13 | Issue: 17 | Pages: 5191

10.3390/jcm13175191 | PMID 39274404 Get It

One of the recent advancements in the field of cardiac electrophysiology is pulsed field ablation (PFA). PFA is a novel energy modality that does not rely on thermal processes to achieve ablation which, in turn, results in limited collateral damage to surrounding structures. In this review, we discuss the mechanisms, safety, efficacy, and clinical applications of PFA for the management of atrial and ventricular arrhythmias. We also summarize the published pre-clinical and clinical studies regarding this new technology.
Travel-Related Cutaneous Myiasis: A Case Report
Mendoza, Alessa Z., Borna, Sahar , Ho, Olivia A. , Waldorf, James C., Borna, Sahar , Ho, Olivia A

Journal of Clinical Medicine | September 2, 2024 | Volume: 13 | Issue: 17 | Pages: 5190

10.3390/jcm13175190 | PMID 39274403 Get It

Background: Human myiasis, the infestation of tissues by dipterous larvae, commonly manifests as painful, raised skin lesions, particularly in tropical regions such as Latin America, where Dermatobia hominis (the human botfly) is a frequent cause. With increased international travel, cases of travel-related myiasis have become more prevalent, necessitating awareness among healthcare providers in non-endemic regions. Methods: We present a case of cutaneous myiasis in a 69-year-old male who returned to the United States from Belize. The patient exhibited a painful skin lesion on his right knee, initially suspected to be an insect bite. The diagnosis was confirmed through ultrasound imaging, which revealed the presence of a subcutaneous larva. Conservative larva removal efforts failed, leading to surgical extraction of the larva. Results: The surgical intervention successfully removed the larva in its entirety, with the wound healing well after the procedure. Pathological examination confirmed the larva as Dermatobia hominis. The patient experienced a satisfactory recovery, with no complications observed during follow-up. Conclusions: This case underscores the importance of considering myiasis in the differential diagnosis of patients presenting with painful skin lesions following travel to tropical regions. As globalization increases, healthcare providers should be vigilant in recognizing and appropriately treating travel-related diseases such as myiasis to ensure prompt and effective care.
Do not forget about transplant patients during disasters
Brown, Ashlyn, Trollinger, Brandon , Sekkarie, Mohamed, Alasfar, Sami , Mohamed, S , Mohamed, Sekkarie , Hommos, Musab S.

Current Opinion in Nephrology & Hypertension | September 2, 2024 | Volume: 33 | Issue: 6 | Pages: 627-635

10.1097/mnh.0000000000001021 | PMID 39221939 Get It

Purpose of review The frequency of natural disasters and man-made conflicts has risen significantly in the past two decades, coinciding with an increase in kidney transplant recipients globally. This review addresses the critical need for disaster preparedness to mitigate the severe impacts on this vulnerable patient cohort. Recent findings Kidney transplant recipients are highly dependent on robust healthcare infrastructures for ongoing care, including specialized medical staff, advanced diagnostics, and a consistent supply of immunosuppressive medications. Disasters disrupt these essential services, leading to increased risks of organ rejection, infections, and other medical complications. Strategies at various levels, from government to individual patients, can help maintain care continuity during such crises. Summary Effective disaster preparedness plans involving strategic medication stockpiling, emergency communication systems, and patient education are crucial to support kidney transplant recipients. By implementing these measures, healthcare systems can better protect the health and well being of transplant patients during and after disasters.
383. LOSS OF PERISTALTIC RESERVE DETERMINED BY MULTIPLE RAPID SWALLOWS CORRELATES WITH DYSPHAGIA AND POOR BOLUS TRANSIT IN INEFFECTIVE ESOPHAGEAL MOTILITY
Sileno, Sean, Vela, Marcelo F. , Crowell, Michael D.

Diseases of the Esophagus | September 2, 2024 | Volume: 37 | Issue: Supplement_1 | Pages: No page available

10.1093/dote/doae057.141 Get It

Abstract Introduction Ineffective esophageal motility (IEM) is a common finding on high resolution esophageal manometry (HRM) and is often of unclear clinical significance as its impact on dysphagia and bolus transit is variable. Multiple rapid swallow (MRS) testing is a provocative maneuver performed during HRM that assesses peristaltic reserve, documented by the presence of contractile augmentation (defined by contractile vigor after MRS greater than that seen with single swallows). Lack of augmentation after MRS is associated with dysphagia after anti-reflux surgery. To date, no studies have evaluated the impact of peristaltic reserve on dysphagia and bolus transit in IEM patients. Methods Retrospective review of 159 patients with Chicago classification 4.0 IEM. 52 patients were excluded due to prior esophageal surgery, technically inadequate MRS, or concomitant esophagogastric junction outflow obstruction. Demographics and brief esophageal dysphagia questionnaire (BEDQ) results were obtained from a prospectively maintained database. MRS and bolus transit data were analyzed using a commercially available software. Impedance analysis documented complete versus incomplete bolus transit. Augmentation was defined as the ratio of post-MRS DCI to mean single swallow DCI &gt; 1. Fisher's exact test for continuous data and linear model ANOVA were used to assess for statistical significance. Results 107 IEM patients were included, 46 of them had loss of peristaltic reserve (no augmentation on MRS). Compared to IEM patients with augmentation, those without augmentation had more severe dysphagia documented by higher mean BEDQ score (6.8 versus 4.8, p= 0.045), and increased rates of impaired bolus transit (73% versus 55%, p-= 0.013). Discussion IEM patients without augmentation on MRS have more severe dysphagia and more frequent incomplete bolus clearance. These findings support adding MRS response to the diagnosis of IEM or using it to describe a subset of patients with more severe disease.
Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells
Qie, Yaqing, To, Tommy, Li, Shuhua, Rivera-Valentín, Rocío K. , Dronca, Roxana , Kharfan‐Dabaja, Mohamed A. , Gadd, Martha E. , Shao, Qing , Yassine, Farah, Shao, Qing , Liu, Andy , Yassine, Farah , Murthy, Hemant S. , Qin, Hong , Luo, Yan

MedComm | September 2, 2024 | Volume: 5 | Issue: 9 | Pages: No page available

10.1002/mco2.716 | PMID 39224539 Get It

AbstractThe challenge of disease relapsed/refractory (R/R) remains a therapeutic hurdle in chimeric antigen receptor (CAR) T‐cell therapy, especially for hematological diseases, with chronic lymphocytic leukemia (CLL) being particularly resistant to CD19 CAR T cells. Currently, there is no approved CAR T‐cell therapy for CLL patients. In this study, we aimed to address this unmet medical need by choosing the B‐cell activating factor receptor (BAFF‐R) as a promising target for CAR design against CLL. BAFF‐R is essential for B‐cell survival and is consistently expressed on CLL tumors. Our research discovered that BAFF‐R CAR T‐cell therapy exerted the cytotoxic effects on both CLL cell lines and primary B cells derived from CLL patients. In addition, the CAR T cells exhibited cytotoxicity against CD19‐knockout CLL cells that are resistant to CD19 CAR T therapy. Furthermore, we were able to generate BAFF‐R CAR T cells from small blood samples collected from CLL patients and then demonstrated the cytotoxic effects of these patient‐derived CAR T cells against autologous tumor cells. Given these promising results, BAFF‐R CAR T‐cell therapy has the potential to meet the long‐standing need for an effective treatment on CLL patients.